A Phase I Single Ascending Dose (SAD) Trial of SNDX-6352 Assessing the Safety, Pharmacokinetics and Pharmacodynamics of the Anti-CSF-1R Monoclonal Antibody (SNDX-6352) in Healthy Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2017
At a glance
- Drugs UCB 6352 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- 10 Aug 2017 Status changed from recruiting to active, no longer recruiting, according to a Syndax Pharmaceuticals media release.
- 02 Mar 2017 According to a Syndax Pharmaceuticals media release, company expects to present data at a scientific congress in the fourth quarter of 2017.
- 10 Nov 2016 Status changed from planning to recruiting, according to a Syndax Pharmaceuticals media release.